Safety and efficacy of mixing cetrorelix with follitropin alfa: a randomized study

Yu Hung Lin, Yeong-Ray Wen, Yuan-May Chang, Kok Min Seow, Bih Chwen Hsieh, Jiann-Loung Hwang, Chii Ruey Tzeng

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To assess the safety and efficacy of mixing cetrorelix with follitropin alfa (rFSH) in assisted reproductive technology. Design: Prospective, randomized study. Setting: An IVF center in a teaching hospital. Patient(s): One hundred forty patients undergoing intracytoplasmic sperm injection were randomized into mixed (M) or separate (S) injection groups. Intervention(s): In the M group, rFSH and cetrorelix were mixed immediately before administration, whereas in the S group, rFSH and cetrorelix were administered separately. Main Outcome Measure(s): The primary efficacy end point was the incidence of premature LH surge. The secondary efficacy endpoints included estradiol levels on the day of hCG injection, numbers of oocytes obtained, implantation, and ongoing pregnancy rates. The safety endpoints included ovarian hyperstimulation syndrome, and adverse events related to injections including local tolerability. Result(s): Excluding eight patients who dropped out of the study, there were 66 patients in each group for analysis. Patients in the M group received significantly fewer injections than patients in the S group (9.1 vs. 13.9). Other outcome parameters, including incidences of premature LH surge, numbers of oocytes retrieved, fertilization, implantation, and ongoing pregnancy rates were similar between the two groups. Conclusion(s): Cetrorelix and rFSH can be mixed together without compromising their reported safety and efficacy. This observation is in line with the reported safety and efficacy profile of the products listed in their current package inserts.

Original languageEnglish
Pages (from-to)179-183
Number of pages5
JournalFertility and Sterility
Volume94
Issue number1
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Safety
Injections
Pregnancy Rate
Oocytes
Product Labeling
Ovarian Hyperstimulation Syndrome
Assisted Reproductive Techniques
Intracytoplasmic Sperm Injections
Incidence
Fertilization
Teaching Hospitals
follitropin alfa
cetrorelix
Estradiol
Outcome Assessment (Health Care)
Prospective Studies

Keywords

  • Cetrorelix
  • FSH
  • premature LH surge
  • visual analogue scale

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Safety and efficacy of mixing cetrorelix with follitropin alfa : a randomized study. / Lin, Yu Hung; Wen, Yeong-Ray; Chang, Yuan-May; Seow, Kok Min; Hsieh, Bih Chwen; Hwang, Jiann-Loung; Tzeng, Chii Ruey.

In: Fertility and Sterility, Vol. 94, No. 1, 06.2010, p. 179-183.

Research output: Contribution to journalArticle

Lin, Yu Hung ; Wen, Yeong-Ray ; Chang, Yuan-May ; Seow, Kok Min ; Hsieh, Bih Chwen ; Hwang, Jiann-Loung ; Tzeng, Chii Ruey. / Safety and efficacy of mixing cetrorelix with follitropin alfa : a randomized study. In: Fertility and Sterility. 2010 ; Vol. 94, No. 1. pp. 179-183.
@article{fc6ee7729663423cb6055fa4731683af,
title = "Safety and efficacy of mixing cetrorelix with follitropin alfa: a randomized study",
abstract = "Objective: To assess the safety and efficacy of mixing cetrorelix with follitropin alfa (rFSH) in assisted reproductive technology. Design: Prospective, randomized study. Setting: An IVF center in a teaching hospital. Patient(s): One hundred forty patients undergoing intracytoplasmic sperm injection were randomized into mixed (M) or separate (S) injection groups. Intervention(s): In the M group, rFSH and cetrorelix were mixed immediately before administration, whereas in the S group, rFSH and cetrorelix were administered separately. Main Outcome Measure(s): The primary efficacy end point was the incidence of premature LH surge. The secondary efficacy endpoints included estradiol levels on the day of hCG injection, numbers of oocytes obtained, implantation, and ongoing pregnancy rates. The safety endpoints included ovarian hyperstimulation syndrome, and adverse events related to injections including local tolerability. Result(s): Excluding eight patients who dropped out of the study, there were 66 patients in each group for analysis. Patients in the M group received significantly fewer injections than patients in the S group (9.1 vs. 13.9). Other outcome parameters, including incidences of premature LH surge, numbers of oocytes retrieved, fertilization, implantation, and ongoing pregnancy rates were similar between the two groups. Conclusion(s): Cetrorelix and rFSH can be mixed together without compromising their reported safety and efficacy. This observation is in line with the reported safety and efficacy profile of the products listed in their current package inserts.",
keywords = "Cetrorelix, FSH, premature LH surge, visual analogue scale",
author = "Lin, {Yu Hung} and Yeong-Ray Wen and Yuan-May Chang and Seow, {Kok Min} and Hsieh, {Bih Chwen} and Jiann-Loung Hwang and Tzeng, {Chii Ruey}",
year = "2010",
month = "6",
doi = "10.1016/j.fertnstert.2009.02.062",
language = "English",
volume = "94",
pages = "179--183",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Safety and efficacy of mixing cetrorelix with follitropin alfa

T2 - a randomized study

AU - Lin, Yu Hung

AU - Wen, Yeong-Ray

AU - Chang, Yuan-May

AU - Seow, Kok Min

AU - Hsieh, Bih Chwen

AU - Hwang, Jiann-Loung

AU - Tzeng, Chii Ruey

PY - 2010/6

Y1 - 2010/6

N2 - Objective: To assess the safety and efficacy of mixing cetrorelix with follitropin alfa (rFSH) in assisted reproductive technology. Design: Prospective, randomized study. Setting: An IVF center in a teaching hospital. Patient(s): One hundred forty patients undergoing intracytoplasmic sperm injection were randomized into mixed (M) or separate (S) injection groups. Intervention(s): In the M group, rFSH and cetrorelix were mixed immediately before administration, whereas in the S group, rFSH and cetrorelix were administered separately. Main Outcome Measure(s): The primary efficacy end point was the incidence of premature LH surge. The secondary efficacy endpoints included estradiol levels on the day of hCG injection, numbers of oocytes obtained, implantation, and ongoing pregnancy rates. The safety endpoints included ovarian hyperstimulation syndrome, and adverse events related to injections including local tolerability. Result(s): Excluding eight patients who dropped out of the study, there were 66 patients in each group for analysis. Patients in the M group received significantly fewer injections than patients in the S group (9.1 vs. 13.9). Other outcome parameters, including incidences of premature LH surge, numbers of oocytes retrieved, fertilization, implantation, and ongoing pregnancy rates were similar between the two groups. Conclusion(s): Cetrorelix and rFSH can be mixed together without compromising their reported safety and efficacy. This observation is in line with the reported safety and efficacy profile of the products listed in their current package inserts.

AB - Objective: To assess the safety and efficacy of mixing cetrorelix with follitropin alfa (rFSH) in assisted reproductive technology. Design: Prospective, randomized study. Setting: An IVF center in a teaching hospital. Patient(s): One hundred forty patients undergoing intracytoplasmic sperm injection were randomized into mixed (M) or separate (S) injection groups. Intervention(s): In the M group, rFSH and cetrorelix were mixed immediately before administration, whereas in the S group, rFSH and cetrorelix were administered separately. Main Outcome Measure(s): The primary efficacy end point was the incidence of premature LH surge. The secondary efficacy endpoints included estradiol levels on the day of hCG injection, numbers of oocytes obtained, implantation, and ongoing pregnancy rates. The safety endpoints included ovarian hyperstimulation syndrome, and adverse events related to injections including local tolerability. Result(s): Excluding eight patients who dropped out of the study, there were 66 patients in each group for analysis. Patients in the M group received significantly fewer injections than patients in the S group (9.1 vs. 13.9). Other outcome parameters, including incidences of premature LH surge, numbers of oocytes retrieved, fertilization, implantation, and ongoing pregnancy rates were similar between the two groups. Conclusion(s): Cetrorelix and rFSH can be mixed together without compromising their reported safety and efficacy. This observation is in line with the reported safety and efficacy profile of the products listed in their current package inserts.

KW - Cetrorelix

KW - FSH

KW - premature LH surge

KW - visual analogue scale

UR - http://www.scopus.com/inward/record.url?scp=77952545779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952545779&partnerID=8YFLogxK

U2 - 10.1016/j.fertnstert.2009.02.062

DO - 10.1016/j.fertnstert.2009.02.062

M3 - Article

C2 - 19339001

AN - SCOPUS:77952545779

VL - 94

SP - 179

EP - 183

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 1

ER -